Pilot Clinical Trial of PRS TB Regimen I - Phase II
Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
Tuberculosis is the current leading cause of death due to an identifiable infectious agent
worldwide. The current standard regimen for tuberculosis requires a patient to take drug
combination (isoniazid, rifampicin, ethambutol, and pyrazinamide) for six to eight month
periods. The purpose of this study is to compare tuberculosis treatment therapy between the
current standard regimen and PRS derived combinatorial regimen. PRS derived regimen may
potentially allow for a shorter course of treatment, which may reduce problems associated
with adherence, toxicity, and development of drug resistance.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborators:
Bill and Melinda Gates Foundation Eighty-fifth Hospital of the PLA,Shanghai,China. No.85 Hospital, Changning, Shanghai, China Shanghai Center for Disease Control and Prevention Shanghai Public Health Clinical Center University of California, Los Angeles